Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

被引：3
|
作者：
Zhou, C. [1 ]
Cheng, Y. [2 ]
He, Y. [3 ]
Li, W. [4 ]
Zhang, H. [5 ]
Zhou, Q. [6 ,7 ]
Wang, B. [8 ]
Liu, C. [9 ]
Ramalingam, S. [10 ]
Walding, A. [11 ]
Saggese, M. [11 ]
Wang, J. [12 ]
Fan, M. [12 ]
Wu, Y. [6 ,7 ]
机构：
[1] Tongji Univ, Pulm Hosp, Shanghai, Peoples R China
[2] Jilin Prov Canc Hosp, Thorac Oncol, Changchun, Jilin, Peoples R China
[3] Daping Hosp, Resp Dis, Chongqing, Peoples R China
[4] Jinlin Univ, Hosp 1, Changchun, Jilin, Peoples R China
[5] Forth Mil Med Univ, Tangdu Hosp, Oncol, Xian, Shaanxi, Peoples R China
[6] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[7] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[8] Yangzhou Univ, Subei PeopleS Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China
[9] Xinjiang Med Univ, Tumor Hosp, Urumqi, Peoples R China
[10] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[11] Astrazeneca, Global Med Dev, Cambridge, England
[12] Astrazeneca, Global Med Dev, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
osimertinib; China; NSCLC;
D O I：
10.1016/j.jtho.2018.08.669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-112
引用
收藏
页码：S507 / S508
页数：2
相关论文
共 50 条
  • [21] Preventing and Treating Brain Metastases with Three First-Line EGFR-TKI in Patients with EGFR Mutation Advanced NSCLC
    Lin, C.
    Su, W.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S484 - S484
  • [22] The Relationship Between Preliminary Efficacy and Prognosis After First-Line EGFR-TKI Treatment of Advanced NSCLC
    Chen, D.
    Chu, T.
    Chang, Q.
    Zhang, Y.
    Xiong, L.
    Qiao, R.
    Teng, J.
    Han, B.
    Zhong, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S937 - S937
  • [23] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Cheng, Ying
    He, Yong
    Li, Wei
    Zhang, He-long
    Zhou, Qing
    Wang, Buhai
    Liu, Chunling
    Walding, Andrew
    Saggese, Matilde
    Huang, Xiangning
    Fan, Minhao
    Wang, Jia
    Ramalingam, Suresh S.
    TARGETED ONCOLOGY, 2021, 16 (02) : 165 - 176
  • [24] Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
    Ying Cheng
    Yong He
    Wei Li
    He-long Zhang
    Qing Zhou
    Buhai Wang
    Chunling Liu
    Andrew Walding
    Matilde Saggese
    Xiangning Huang
    Minhao Fan
    Jia Wang
    Suresh S. Ramalingam
    Targeted Oncology, 2021, 16 : 165 - 176
  • [25] A Comparison of Sequential EGFR-TKI Therapy Versus First-Line Osimertinib in NSCLC: A Multi-Center, Retrospective Study
    Lee, C.
    Miao, E.
    Chung, S.
    Ahmed, I.
    Kohn, N.
    Patel, K.
    Stefanov, D.
    Seetharamu, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S589 - S589
  • [26] Safety of tepotinib plus EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
    Nadal, E.
    Kim, T. M.
    Guarneri, V.
    Voon, P. J.
    Lim, B. K.
    Wislez, M.
    Huang, C.
    Liam, C. K.
    Mazieres, J.
    Tho, L. M.
    Hayashi, H.
    Nguyen, N.
    Chia, P. L.
    De Marinis, F.
    Brutlach, S.
    Adrian, S.
    Ellers-Lenz, B.
    Berghoff, K.
    Karachaliou, N.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [27] Real-World Outcomes and Treatment Patterns after First-Line Osimertinib in Patients with Advanced NSCLC and Uncommon EGFRm
    Nieva, J.
    Chapaneri, J.
    Lau, Y. K.
    Cooper, M.
    Karia, P. S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S191 - S191
  • [28] CLINICAL OUTCOMES AFTER FIRST-LINE EGFR-TKI FOR PATIENTS WITH NSCLC, EGFR MUTATION, AND POOR PERFORMANCE STATUS
    Nagamata, Makoto
    Okuma, Yusuke
    Sunami, Kuniko
    Hosomi, Yukio
    Okamura, Tatsuru
    ANNALS OF ONCOLOGY, 2014, 25
  • [29] Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) NSCLC
    Wehler, T.
    Wehler, B.
    Atmaca-Dirik, H.
    Schulz, C.
    Grohe, C.
    Topsch, J.
    Ehrlich, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S800 - S801
  • [30] Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
    Shu, Yamin
    Ding, Yufeng
    He, Xucheng
    Liu, Yanxin
    Wu, Pan
    Zhang, Qilin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345